Research at InfectoPharm – An international team of investigators has just published the long-awaited FORTRESS study in the renowned scientific journal „Infectious Diseases and Therapy“. The landmark research paper provides crucial insights into the effectiveness and safety of intravenous IV Fosfomycin (FOS).
In the context of antimicrobial resistance (AMR) – an increasing threat to global public health – intravenous FOS has recently experienced a remarkable renaissance, primarily as a combination partner to other antibiotics for the treatment of difficult‑to‑treat (DTR) infections.
Why choose fosfomycin?
- Broad-spectrum activity
- Effective against both Gram-positive and Gram-negative pathogens
- Suitable for various severe infection types
The study addresses the effectiveness and safety of IV Fosfomycin in treating severe infections under real-world conditions, including infections caused by multi-drug resistant bacteria.
The full publication is available as free access, allowing the wider medical community to benefit from these important findings, too: To the Study
Our sincere thanks to all international investigators and the InfectoPharm team for their outstanding contributions.
#FORTRESS #AntimicrobialResistance #InfectiousDiseases